The mitochondria‐targeted antioxidant MitoQ was well tolerated in a Phase II trial in chronic hepatitis C patients, significantly lowering ALT levels and reducing necroinflammatory liver damage, likely via mtROS scavenging (Murray et al., 2022; Gane et al., 2010). This evidence concerns the gene GPT and chronic hepatitis C virus infection.